Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1975 3
1976 1
1977 3
1978 1
1979 2
1980 5
1981 8
1982 9
1983 9
1984 11
1985 17
1986 13
1987 19
1988 23
1989 24
1990 20
1991 21
1992 31
1993 35
1994 27
1995 31
1996 39
1997 41
1998 61
1999 61
2000 65
2001 57
2002 81
2003 73
2004 102
2005 120
2006 154
2007 160
2008 202
2009 229
2010 270
2011 301
2012 344
2013 371
2014 449
2015 520
2016 503
2017 520
2018 672
2019 701
2020 833
2021 907
2022 1000
2023 992
2024 431

Text availability

Article attribute

Article type

Publication date

Search Results

9,518 results

Results by year

Filters applied: . Clear all
Page 1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: yu g. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Lu S, et al. Among authors: yu g. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. JAMA. 2024. PMID: 38227033 Clinical Trial.
Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, Edupuganti VVSR, Hsu KS, Dower C, Yu G, So D, Bajgain P, Zhu Z, Dimitrov DS, Patel NL, Robinson CM, Difilippantonio S, Dyba M, Corbel A, Basuli F, Swenson RE, Kalen JD, Suthe SR, Hussain M, Italia JS, Souders CA, Gao L, Schnermann MJ, St Croix B. Feng Y, et al. Among authors: yu g. Cell Rep. 2023 Dec 26;42(12):113503. doi: 10.1016/j.celrep.2023.113503. Epub 2023 Nov 28. Cell Rep. 2023. PMID: 38019654 Free PMC article.
Fractional quantum ferroelectricity.
Ji J, Yu G, Xu C, Xiang HJ. Ji J, et al. Among authors: yu g. Nat Commun. 2024 Jan 2;15(1):135. doi: 10.1038/s41467-023-44453-y. Nat Commun. 2024. PMID: 38167841 Free PMC article.
Cellular Senescence: A Troy Horse in Pulmonary Fibrosis.
Wan R, Wang L, Zhu M, Li W, Duan Y, Yu G. Wan R, et al. Among authors: yu g. Int J Mol Sci. 2023 Nov 16;24(22):16410. doi: 10.3390/ijms242216410. Int J Mol Sci. 2023. PMID: 38003600 Free PMC article. Review.
9,518 results